ADMA BIOLOGICS, INC. financials

  1. Home
  2. Financials
  3. ADMA
ADMA CIK 0001368514

Source: EDGAR filings · Built 2026-06-02T02:14:45Z

Key metrics by reporting period

Up to six most-recent periods side-by-side. Rows are the curated key lines — revenue, margins, cash, debt, equity, cash-flow totals, plus the derived and valuation metrics we compute on top. For every tag a filer reported in one period, use the single-filing drilldown below.

Derived Metrics

Concept FY 2025FY 2024FY 2023FY 2022FY 2021FY 2020
Free Cash Flow 27.82M 110.45M 4.01M -73.45M -125.91M -114.76M
EBITDA 199.44M 146.68M 29.23M -32.97M -53.57M -61.71M
Working Capital 396.97M 275.87M 207.21M 231.13M 178.35M 133.79M
Net Debt -7.75M -21.03M 90.07M 67.92M 51.83M 134.72M
Gross Margin 57.39% 51.48% 34.44% 22.89% 1.45% -45.17%
Operating Margin 37.53% 32.59% 8.38% -25.55% -72.12% -153.75%
Net Margin 28.80% 46.35% -10.94% -42.77% -88.52% -179.41%
Return on Equity (ROE) 30.78% 56.64% -20.89% -43.37% -50.75% -85.83%
Return on Assets (ROA) 23.54% 40.45% -8.58% -18.91% -25.94% -36.47%
Current Ratio 6.71× 5.97× 5.16× 6.89× 6.87× 7.71×
Debt-to-Equity 0.17× 0.24× 1.05× 1.02× 0.73× 2.16×
Effective Tax Rate 19.56% -57.24% 0.00% 0.00% — —
Cash Conversion Ratio 0.34× 0.60× -0.31× 0.90× 1.57× 1.35×
Accruals Ratio 0.15× 0.16× -0.11× -0.02× 0.15× 0.13×
SBC % of Revenue 3.93% 3.19% 2.40% 3.38% 4.31% 6.76%
CapEx Coverage 2.23× 14.43× 1.84× -4.27× -8.30× -7.99×
Free Cash Flow Per Share $0.11 $0.45 $0.02 $-0.37 $-0.90 $-1.33

Valuation Metrics

Concept FY 2025FY 2024FY 2023FY 2022FY 2021FY 2020
P/E Trailing (Diluted) 30.40× 21.17× — — — —
P/FCF 160.56× 37.78× 252.51× — — —
FCF Yield 0.62% 2.65% 0.40% — — —
EV / EBITDA 21.72× 27.52× 38.04× — — —
P/S 8.50× 9.52× 3.96× 5.59× 3.41× 4.85×
P/B 9.09× 11.63× 7.56× 5.66× 1.96× 2.32×

Income Statement

Concept FY 2025FY 2024FY 2023FY 2022FY 2021FY 2020
Revenue from Contract with Customer, Excluding Assessed Tax 510.17M 426.45M 258.21M 154.08M 80.94M 42.22M
Revenues — — — — — 42.22M
Cost of Revenue 217.41M 206.90M 169.27M 118.81M 79.77M 61.29M
Gross Profit 292.76M 219.55M 88.94M 35.27M 1.17M -19.07M
Research and Development Expense 4.76M 1.81M 3.30M 3.61M 3.65M 5.91M
Selling, General and Administrative Expense 91.58M 74.12M 59.02M 52.46M 42.90M 35.05M
Operating Expenses 101.32M 80.57M 67.31M 74.63M 59.55M 45.84M
Operating Income (Loss) 191.44M 138.98M 21.63M -39.37M -58.37M -64.91M
Income Tax Expense (Benefit) 35.73M -71.96M 0 0 0 0
Net Income (Loss) Attributable to Parent 146.93M 197.67M -28.24M -65.90M -71.65M -75.75M
Earnings Per Share, Basic $0.62 $0.85 $-0.13 $-0.33 $-0.51 $-0.88
Weighted Average Number of Shares Outstanding, Basic 238.30M 233.08M 223.98M 197.87M 139.58M 86.15M
Earnings Per Share, Diluted $0.60 $0.81 $-0.13 $-0.33 $-0.51 $-0.88
Weighted Average Number of Shares Outstanding, Diluted 244.90M 243.34M 223.98M 197.87M 139.58M 86.15M

Balance Sheet

Concept FY 2025FY 2024FY 2023FY 2022FY 2021FY 2020
Cash and Cash Equivalents, at Carrying Value 87.63M 103.15M 51.35M 86.52M 51.09M 55.92M
Assets, Current 466.51M 331.41M 257.01M 270.40M 208.73M 153.74M
Assets 624.24M 488.68M 329.18M 348.46M 276.25M 207.67M
Long-term Debt 72.14M 72.34M — — — —
Liabilities, Current 69.54M 55.54M 49.81M 39.27M 30.38M 19.95M
Long-term Debt, Excluding Current Maturities 69.33M 72.34M — — — —
Liabilities 146.92M 139.66M 193.98M 196.49M 135.08M 119.42M
Stockholders' Equity Attributable to Parent 477.32M 349.02M 135.21M 151.97M 141.17M 88.25M
Common Stock, Shares, Outstanding 237.87M 236.62M 226.06M 221.82M 195.81M 104.90M

Cash Flow Statement

Concept FY 2025FY 2024FY 2023FY 2022FY 2021FY 2020
Net Cash Provided by (Used in) Operating Activities 50.40M 118.67M 8.80M -59.51M -112.37M -102.00M
Payments to Acquire Property, Plant, and Equipment 22.57M 8.23M 4.77M 13.91M 13.51M 12.73M
Net Cash Provided by (Used in) Investing Activities -21.89M -8.57M -4.98M -13.91M -13.51M -12.72M
Payments for Repurchase of Common Stock 31.94M 0 0 — — —
Net Cash Provided by (Used in) Financing Activities -44.02M -58.30M -38.99M 108.85M 121.05M 143.90M

Raw XBRL tagging for a single filing

Every us-gaap and custom concept the filer tagged for one fiscal period, grouped by statement. Start here when a number in the trend table above surprises you and you want to see the exact tag behind it. Derived and valuation rows are omitted here because they already appear in the trend table.

Most recent filing shown by default.

Compare filings side-by-side

Diff any two filings with deltas and added / removed tags.

Immaterial rows are USD line items under 1% of the period's revenue — the noise floor below which a single tag rarely moves the investment thesis. Revenue is read from the filer's top-line concept (Revenues / RevenueFromContractWithCustomerExcludingAssessedTax, with a fallback chain). Non-USD rows, rows without a numeric value, and every row on a filing with no identifiable revenue anchor stay visible. Flip the switch off to see every tag the filer reported for the period.

Loading filing details…

Methodology

All facts on this page come straight from SEC EDGAR XBRL company-facts filings (ADMA CIK 0001368514), grouped by financial statement using FASB's base us-gaap presentation taxonomy. Filers may re-parent concepts onto different statements in their own extension taxonomy, so a handful of rows can show up under a different statement than on the actual 10-K / 10-Q; custom concepts and any we couldn't map fall into Other. Hover a cell to see the fully-qualified concept name and the filer's description.

For the full methodology — statement grouping, the Other bucket, derived metrics, and fact tooltips — see the methodology reference for the statement grouping, the "Other" bucket, derived metrics, and fact tooltips.

Related tickers

PL

PLANET LABS PBC

ALGT

ALLEGIANT TRAVEL COMPANY

FULT

FULTON FINANCIAL CORP